Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, valuing the deal at approximately $10 billion equity value. The acquisition aims to strengthen Vertex's endocrinology portfolio with two key assets—PALSONIFY and atumelnant—which are projected to reach combined peak annual sales of over $5 billion.